eligibility_summary
Inclusion: Adults (≥18) on ocrelizumab, at least 4th 6-monthly cycle, follow-up MRI needed, indication per label (active RR/SP MS), relapse-free ≥18 months, EDSS 0–6, consent, French-speaking, insured. Exclusion: PPMS, dosing intervals ≥9 months, contraindication to ocrelizumab, MRI or contrast, planned pregnancy within 3 years, severe/uncontrolled comorbidity, under legal protection, no effective contraception, pregnant or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Ocrelizumab (Ocrevus), a humanized IgG1 anti‑CD20 monoclonal antibody given by IV infusion. Mechanism: binds CD20 on B lymphocytes and depletes them via ADCC, CDC, and apoptosis, dampening antigen presentation to T cells, B‑cell cytokine production, and pathogenic humoral responses, hematopoietic stem cells and plasma cells are largely spared. Targets/pathways: CD20+ B‑cell lineage (naïve and memory B cells), B‑cell–T‑cell crosstalk, and downstream adaptive immune/inflammatory pathways driving MS lesion activity. Trial design: multicenter randomized non‑inferiority comparison of annual versus standard 6‑monthly ocrelizumab dosing after ≥2 years of prior therapy, aiming to maintain radiological disease control while potentially reducing infection risk linked to cumulative exposure and hypogammaglobulinemia.